Morning Overview on MSN

Study shows chemo drug azacitidine damages RNA in stressed cells

The chemotherapy drug azacitidine, a frontline treatment for blood cancers such as myelodysplastic syndromes and acute ...
Cure Today

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

Azacitidine/Venclexta improved EFS and quality of life compared to induction chemotherapy in fit AML patients, with a 39% risk reduction in disease progression or death. The PARADIGM trial showed a ...
The American Journal of Managed Care

Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction chemotherapy in AML patients. The study highlighted reduced hospital stays, ...
Healio

‘Profound’ data show azacitidine plus venetoclax significantly benefits patients with AML

Please provide your email address to receive an email when new articles are posted on . Azacitidine plus venetoclax significantly improved EFS compared with induction chemotherapy for certain patients ...
ascopubs.org

A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer.

Influence of genetic variants of genes potentially associated with colorectal brain metastases on overall survival. This is an ASCO Meeting Abstract from the 2014 Gastrointestinal Cancers Symposium.
Healio

Five-day azacitidine best among shorter hypomethylating agent regimens for low-risk MDS

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...